Publications

Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.

Demichelis F, Garraway LA, Rubin MA.  2013.  Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.. Cancer Cell. 23(2):133-5.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2015.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol. 26(8):1589-604.

Mosquera J-M, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ.  2015.  MAGI3-AKT3 fusion in breast cancer amended.. Nature. 520(7547):E11-2.

Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM et al..  2004.  JAGGED1 expression is associated with prostate cancer metastasis and recurrence.. Cancer Res. 64(19):6854-7.

Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.  2005.  Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.

Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C et al..  2016.  Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.. Sci Rep. 6:24146.

Hofer MD, Browne TJ, He L, Skotheim RI, Lothe RA, Rubin MA.  2005.  Identification of two molecular groups of seminomas by using expression and tissue microarrays.. Clin Cancer Res. 11(16):5722-9.

Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA.  2005.  Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.. Cancer Res. 65(13):5750-60.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.  2004.  Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.. J Natl Cancer Inst. 96(11):834-43.

Andrén O, Fall K, Franzén L, Andersson S-O, Johansson J-E, Rubin MA.  2006.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 175(4):1337-40.

Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..  2005.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.

Demichelis F, Magni P, Piergiorgi P, Rubin MA, Bellazzi R.  2006.  A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays.. BMC Bioinformatics. 7:514.

Rubin MA.  2015.  Health: Make precision medicine work for cancer care.. Nature. 520(7547):290-1.

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..  2009.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.

Elemento O, Rubin MA.  2016.  Genomic Testing & Precision Medicine: Bigger Is Better.

Barbieri CE, Rubin MA.  2015.  Genomic rearrangements in prostate cancer.. Curr Opin Urol. 25(1):71-6.

Rubin MA, Girelli G, Demichelis F.  2016.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.. Eur Urol. 69(4):557-60.